Product Description
Choline fenofibrate is a newly developed choline salt of fenofibric acid, which is more hydrophilic than fenofibrate. Choline fenofibrate delayed release 135 mg is as safe and effective as 160 mg of micronized fenofibrate in Indian patients with mixed dyslipidemia. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743387/)
Mechanisms of Action: PPAR-a Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Chile | Dominican Republic | Ecuador | India | Korea | Russia | Singapore | Switzerland | Taiwan | Thailand | Ukraine
Approved Indications: None
Known Adverse Events: None
Company: Abbott Laboratories
Company Location: ABBOTT PARK IL 60064-3500
Company CEO: Robert B. Ford
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Type 2 Diabetes|Dyslipidemia|Atherosclerosis|Carotid Artery Diseases
Phase 3: Coronary Artery Disease|Dyslipidemia|Myocardial Ischemia|Hypertriglyceridemia|Hypercholesterolemia|Atherosclerosis
Phase 2: Macular Edema|Dyslipidemia|Multiple Myeloma|Medulloblastoma|Ependymoma|COVID-19|Alcoholism
Phase 1: Tobacco Use Disorder|Healthy Volunteers|Hypertriglyceridemia|Dyslipidemia|Hyperlipidemia|Hypertension|Other|Hypercholesterolemia
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20244916 |
CTR20244916 | N/A |
Completed |
Hypercholesterolemia|Hypertriglyceridemia|Dyslipidemia |
2025-04-25 |
2025-05-11 |
Primary Completion Date|Study Completion Date |
|
CTR20242471 |
CTR20242471 | N/A |
Completed |
Hypertriglyceridemia|Dyslipidemia|Hypercholesterolemia|Type 2 Diabetes|Coronary Disease |
2024-09-25 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20234116 |
CTR20234116 | N/A |
Completed |
Hypertriglyceridemia|Hypercholesterolemia|Dyslipidemia |
2024-01-08 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20233224 |
CTR20233224 | N/A |
Completed |
Dyslipidemia|Hypertriglyceridemia|Hypercholesterolemia |
2023-12-08 |
2025-04-29 |
||
CTR20222512 |
CTR20222512 | N/A |
Completed |
Dyslipidemia|Hypertriglyceridemia|Hypercholesterolemia |
2023-01-30 |
2025-04-29 |
||
CTR20221279 |
CTR20221279 | N/A |
Completed |
Hypertriglyceridemia|Dyslipidemia|Hypercholesterolemia |
2022-09-13 |
2025-04-29 |
||
CTR20191478 |
CTR20191478 | N/A |
Completed |
Hypercholesterolemia|Hypertriglyceridemia|Dyslipidemia |
2020-01-16 |
2025-04-29 |
Patient Enrollment|Treatments |
|
CTR20192094 |
CTR20192094 | N/A |
Completed |
Dyslipidemia|Hypertriglyceridemia|Hypercholesterolemia |
2019-11-20 |
2025-04-29 |
Patient Enrollment|Treatments |
|
NCT01974297 |
AVOCADO | N/A |
Unknown status |
Hyperlipidemia|Hyperlipoproteinemia Type V|Hyperlipoproteinemias|Lipidoses |
2014-06-01 |
2019-03-20 |
Treatments |
|
CTR20190653 |
CTR20190653 | P1 |
Completed |
Hypertriglyceridemia|Hypercholesterolemia|Dyslipidemia |
2019-06-11 |
2025-04-29 |
Start Date|Treatments |
|
NCT02422030 |
146DDI14030 | P1 |
Completed |
Healthy Volunteers |
2015-03-22 |
2019-03-20 |
Treatments |
|
NCT01964365 |
DW_DWJ1330001 | P1 |
Completed |
Healthy Volunteers |
2013-12-01 |
2019-03-20 |
||
NCT01501435 |
CJ_FEN_101 | P1 |
Completed |
Healthy Volunteers |
2012-04-01 |
2020-07-16 |
Primary Endpoints|Treatments |
|
NCT01555398 |
HM-FEN-102 | P1 |
Completed |
Healthy Volunteers |
2012-03-01 |
2019-03-19 |
Treatments |
|
NCT01509196 |
HM-FEN-101 | P1 |
Completed |
Healthy Volunteers |
2011-12-01 |
2019-03-19 |
Treatments |
|
NCT01472380 |
MPC-028-11-1001 | P1 |
Completed |
Tobacco Use Disorder |
2011-12-01 |
2019-03-19 |
Treatments |
|
NCT01356290 |
MEMMAT | P2 |
Recruiting |
Medulloblastoma|Ependymoma |
2030-04-01 |
2024-11-27 |
Primary Endpoints|Treatments |
|
NCT04517396 |
FERMIN | P2 |
Completed |
COVID-19 |
2022-03-30 |
2024-03-22 |
Primary Endpoints |
|
NCT02158273 |
Investigating PPAR Agonists | P2 |
Completed |
Alcoholism |
2016-04-01 |
2019-03-20 |
Treatments |
|
NCT01965834 |
NCT01965834 | P2 |
Terminated |
Multiple Myeloma |
2016-03-21 |
2019-03-20 |
Treatments |
|
CTR20160753 |
CTR20160753 | P3 |
Completed |
Dyslipidemia|Hypertriglyceridemia|Hypercholesterolemia |
2019-07-24 |
2025-04-29 |
Patient Enrollment|Start Date|Treatments |
|
NCT00616772 |
FIRST | P3 |
Completed |
Coronary Artery Disease|Dyslipidemia|Myocardial Ischemia |
2012-09-01 |
2019-03-18 |
Treatments |
|
NCT00973271 |
PV011 | P3 |
Withdrawn |
Hypertriglyceridemia |
2011-11-01 |
2019-03-19 |
Treatments |
|
NCT05365425 |
B-2111-720-003 | P4 |
Recruiting |
Atherosclerosis|Type 2 Diabetes|Dyslipidemia|Carotid Artery Diseases |
2025-12-31 |
2024-04-30 |
||
NCT03829514 |
Pro00079289 | P4 |
Completed |
Type 2 Diabetes |
2020-03-04 |
2022-02-10 |
Patient Enrollment|Primary Endpoints|Treatments |